

REGISTERED NUMBER: 03761135 (England and Wales)

**Strategic Report, Report of the Directors and**  
**Financial Statements**  
**for the Year Ended 30 June 2020**  
**for**  
**Catalent Pharma Solutions Limited**



**Catalent Pharma Solutions Limited (Registered number: 03761135)**

**Contents of the Financial Statements**  
**for the Year Ended 30 June 2020**

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Strategic Report</b>	<b>2</b>
<b>Report of the Directors</b>	<b>3</b>
<b>Report of the Independent Auditors</b>	<b>5</b>
<b>Income Statement</b>	<b>7</b>
<b>Statement of Financial Position</b>	<b>8</b>
<b>Statement of Changes in Equity</b>	<b>9</b>
<b>Notes to the Financial Statements</b>	<b>10</b>

**Catalent Pharma Solutions Limited (Registered number: 03761135)**

**Company Information**  
**for the Year Ended 30 June 2020**

**DIRECTORS:**

A Maselli  
A Gennadios  
J Arnold

**SECRETARY:**

A Reed

**REGISTERED OFFICE:**

Frankland Road  
Blagrove  
Swindon  
Wiltshire  
SN5 8YG  
United Kingdom

**REGISTERED NUMBER:**

03761135 (England and Wales)

**AUDITORS:**

Ernst & Young LLP  
The Paragon  
Counterslip  
Bristol  
BS1 6BX

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Strategic Report**  
**for the Year Ended 30 June 2020**

The directors present their strategic report for the year ended 30 June 2020.

**PRINCIPAL ACTIVITY**

The principal activity of the company in the year under review was that of management activities.

**REVIEW OF BUSINESS**

The loss for the year after taxation amounted to £5,640k (2019: loss of £7,973k).

The company's key financial and other performance indicators during the year were as follows:

	2020	2019	Change
	£'000	£'000	%
Turnover	-	-	-%
Total operating loss	(16)	(102)	84%
Shareholders' funds	39,589	45,229	(12%)

**Future developments**

The business intends to continue operating principally as a holding company for the foreseeable future.

**Principal risks and uncertainties**

- Legislative/regulatory risks: Currently the company is regulated by various national regulatory bodies, with the main ones being MHRA in UK and FDA in the USA. Regulatory changes may raise risks as to the company's abilities to service these markets, either impacting its capabilities or impacting it indirectly through changes to customers' product requirements. The company is upgrading its capabilities and systems continuously to ensure it meets all current and reasonably foreseen regulatory changes.

- Economic risks: Through the normal course of its activities, the company has exposure to economics risks specifically interest rates and foreign exchange fluctuations. The company borrowings are with group entities where it pays a variable interest rate. Due to the global nature of the borrowings the company is exposed to exchange variations, mainly for its Euro denominated loan principal and interest. There are no currency hedges or other financial instruments in place at company level to protect against exchange rates variations. Such risks are managed by the company's treasury function at corporate level.

- Other risks: As predominantly a non-trading holding company, the risks of the entity are limited to those economic risks outlined above.

**ON BEHALF OF THE BOARD:**

DocuSigned by:

*Jonathan Arnold*

E3F3CD5850B4429...

J Arnold - Director

10-Dec-2020

Date: .....

**Catalent Pharma Solutions Limited (Registered number: 03761135)**

**Report of the Directors**  
**for the Year Ended 30 June 2020**

The directors present their report with the financial statements of the company for the year ended 30 June 2020.

**GOING CONCERN**

The company's business activities, together with the factors likely to affect its future development and position, are set out in the strategic report.

The company has limited activity and has limited cash flows outside of the Catalent Inc ("Catalent") group. It is in a net liabilities position as of 30 June 2020 and is therefore reliant on the support of Catalent to satisfy the going concern assumption. The impact of COVID-19 (coronavirus) on global economic development is currently unpredictable, however Catalent has significant liquidity headroom as a result of the continued successful operational performance of the Group.

The company has received a support letter from Catalent and in light of that the directors have viewed the going concern of the business for a period of at least 12 months from the approval date and having assessed the responses of the management of Catalent to their enquiries, have no reason to believe that a material uncertainty exists that may cast significant doubt on the ability of the Catalent group to continue as a going concern and therefore to continue to provide support to the entity as and when it is required. On the basis of their assessment of the company's financial position and relevant enquiries, the directors have a reasonable expectation that the company will be able to access the support of Catalent as and when required and thus be able to continue in operational existence for the foreseeable future. Thus, the directors continue to adopt the going concern basis of accounting in preparing the annual financial statements.

**DIVIDENDS**

No dividends were distributed for the year ended 30 June 2020 (2019: nil).

**DIRECTORS**

The directors shown below have held office during the whole of the period from 1 July 2019 to the date of this report.

A Maselli  
A Gennadios  
J Arnold

K Walsh resigned as secretary on 30 August 2019.

**POLITICAL CONTRIBUTIONS**

The company made no political donations during the current or previous year.

**DIRECTORS' INDEMNITY INSURANCE**

The company has granted an indemnity to one or more of its directors against liability in respect of proceedings brought by third parties, subject to the conditions set out in section 234 of the Companies Act 2006. Such qualifying third party indemnity provision remains in force as at the date of approving the directors' report.

**EMPLOYEE INVOLVEMENT**

The company places considerable value on the involvement of its employees and has continued its previous practice of keeping them informed on matters affecting them as employees and on the various factors affecting the performance of the company. Regular briefings cover matters of interest affecting the local site and the company's ultimate parent company, Catalent Pharma Solutions Inc.

**Catalent Pharma Solutions Limited (Registered number: 03761135)**  
**Report of the Directors - continued**  
**for the Year Ended 30 June 2020**

**STATEMENT OF DIRECTORS' RESPONSIBILITIES**

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including "Financial Reporting Standard 102 'The Financial Reporting Standard applicable to the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice)". Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether United Kingdom Generally Accepted Accounting Practice has been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS**

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

**AUDITORS**

An elective resolution has been passed to dispense with the obligations to reappoint Ernst & Young LLP as auditors on an annual basis.

**ON BEHALF OF THE BOARD:**

DocuSigned by:

*Jonathan Arnold*

.....E3F3CD5850B4429.....

J Arnold - Director

10-Dec-2020

Date: .....

**Report of the Independent Auditors to the Members of**  
**Catalent Pharma Solutions Limited**

**Opinion**

We have audited the financial statements of Catalent Pharma Solutions Limited for the year ended 30 June 2020 which comprise the Income Statement, the Statement of Comprehensive Income, the Statement of Changes in Equity, the Statement of Financial Position and the related notes 1 to 18, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the company's affairs as at 30 June 2020 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report below. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Emphasis of matter - Effects of COVID-19**

We draw attention to Note 2 of the financial statements, which describes the economic and social consequences the company is facing as a result of COVID-19 which is impacting the entities ability to continue as a going concern. Our opinion is not modified in respect of this matter.

**Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and directors' report have been prepared in accordance with applicable legal requirements.

**Report of the Independent Auditors to the Members of**  
**Catalent Pharma Solutions Limited (continued)**

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of directors**

As explained more fully in the directors' responsibilities statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**Use of our report**

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

*Ernst & Young LLP*

Jane Barwell (Senior Statutory Auditor)  
for and on behalf of Ernst & Young LLP, Statutory Auditor  
Bristol

Date: 15 December 2020



**Catalent Pharma Solutions Limited (Registered number: 03761135)****Income Statement**  
**for the Year Ended 30 June 2020**

	Notes	2020 £'000	2019 £'000
<b>TURNOVER</b>		-	-
Other operating costs		<u>(16)</u>	<u>(102)</u>
<b>OPERATING LOSS</b>	4	(16)	(102)
Income from investments	5	3,482	-
Interest payable and similar charges	6	(10,486)	(7,871)
Interest receivable and similar income	7	1,380	-
		<u>          </u>	<u>          </u>
<b>LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION</b>		(5,640)	(7,973)
Tax credit on ordinary activities	8	<u>-</u>	<u>-</u>
<b>LOSS FOR THE FINANCIAL YEAR</b>		<u>(5,640)</u>	<u>(7,973)</u>

The company does not have any unrecognised profits or losses other than the above and therefore no separate statement of other comprehensive income has been presented.

There is no material difference between the loss on ordinary activities before tax and the loss for the financial year stated above and their historical equivalents.

All amounts relate to continuing activities.

The notes from 1 to 18 form part of these financial statements.

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Statement of Financial Position**  
**for the Year Ended 30 June 2020**

	Notes	2020 £'000	2019 £'000
<b>FIXED ASSETS</b>			
Investments	9	<u>336,250</u>	<u>363,671</u>
<b>CURRENT ASSETS</b>			
Debtors: amounts falling due within one year	10	83,707	4,577
Debtors: amounts falling due after more than one year	10	4,144	4,144
Cash at bank		<u>63</u>	<u>67</u>
		87,914	8,788
<b>CREDITORS</b>			
Amounts falling due within one year	11	<u>384,575</u>	<u>327,230</u>
<b>NET CURRENT LIABILITIES</b>		<u>(296,661)</u>	<u>(318,442)</u>
<b>NET ASSETS</b>		<u>39,589</u>	<u>45,229</u>
<b>CAPITAL AND RESERVES</b>			
Called up share capital	12	-	-
Retained earnings	13	<u>39,589</u>	<u>45,229</u>
<b>SHAREHOLDERS' FUNDS</b>		<u>39,589</u>	<u>45,229</u>

10-Dec-2020

The financial statements were approved by the Board of Directors on ..... and were signed on its behalf by:

DocuSigned by:

*Jonathan Arnold*

E3F3C0585084429.....

J Arnold - Director

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Statement of Changes in Equity**  
**for the Year Ended 30 June 2020**

	Notes	Retained earnings £'000	Total equity £'000
<b>Balance at 1 July 2018</b>		53,202	53,202
Loss for the year		(7,973)	(7,973)
Total comprehensive income for the year		<u>(7,973)</u>	<u>(7,973)</u>
<b>Balance at 30 June 2019</b>		<u>45,229</u>	<u>45,229</u>
Loss for the year		(5,640)	(5,640)
Total comprehensive income for the year		<u>(5,640)</u>	<u>(5,640)</u>
<b>Balance at 30 June 2020</b>		<u><u>39,589</u></u>	<u><u>39,589</u></u>

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Notes to the Financial Statements**  
**for the Year Ended 30 June 2020****1. STATEMENT OF COMPLIANCE**

Catalent Pharma Solutions Limited is a limited liability company incorporated in England. The Registered Office is Frankland Road, Blagrove, Swindon, Wiltshire, SN5 8YG.

The company's financial statements have been prepared in compliance with Financial Reporting Standard 102 (FRS102) issued by the Financial Reporting Council. The financial statements were authorised for issue by the board of directors on 10 December 2020.

**2. ACCOUNTING POLICIES****Basis of preparing the financial statements**

The financial statements have been prepared in accordance with applicable accounting standards. The financial statements are prepared in pounds sterling which is the functional currency of the company and rounded to the nearest thousand.

The financial statements present information about the company as an individual undertaking and not about its group. The company has taken advantage of the exemption from preparing consolidated accounts by virtue of section 401 of the Companies Act 2006, as it is a wholly owned subsidiary of Catalent Pharma Solutions Inc., for whom consolidated accounts are available to the public. Details can be found in note 17.

**Going concern**

The Company has limited activity and has limited cash flows outside of the Catalent Inc ("Catalent") group. It is in a net current liabilities position as of 30 June 2020 and is therefore reliant on the support of Catalent to satisfy the going concern assumption. The impact of COVID-19 (coronavirus) on global economic development is currently unpredictable, however Catalent has significant liquidity headroom as a result of the continued successful operational performance of the Group. The company has received a support letter from Catalent and in light of that the directors have viewed the going concern of the business for a period of at least 12 months from the approval date and having assessed the responses of the management of Catalent to their enquiries, have no reason to believe that a material uncertainty exists that may cast significant doubt on the ability of the Catalent group to continue as a going concern and therefore to continue to provide support to the entity as and when it is required. On the basis of their assessment of the Company's financial position and relevant enquiries, the directors have a reasonable expectation that the Company will be able to access the support of Catalent as and when required and thus be able to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

**Financial reporting standard 102 - reduced disclosure exemptions**

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows.
- the requirements of Section 33 Related Party Disclosures.

**Significant judgements and estimates**

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates. The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

**Investments** - Investments are stated at their historic cost to the company less, where appropriate, impairment provisions for any permanent or temporary diminution in value. The determination of the recoverable amount of an investment involves the use of estimates by management.

There are no significant estimates.

**Turnover**

Revenue is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, VAT and other sales taxes or duty.

**Catalent Pharma Solutions Limited (Registered number: 03761135)**

**Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020**

**2. ACCOUNTING POLICIES - continued**

**Turnover (continued)**

The following criteria must also be met before revenue is recognised:

**Interest income**

Revenue is recognised as interest accrues using the effective interest method.

**Dividends**

Revenue is recognised when the company's right to receive payment is established.

**Fixed asset investments**

Fixed asset investments are stated at cost less provisions for any diminution in value on a line by line basis.

**Impairment of non-financial assets**

At each reporting date assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. The recoverable amount of the asset is the higher of the fair value less costs to sell and value in use. Value in use is defined as the present value of the future cash flows before interest and tax obtainable as a result of the asset's continued use. These cash flows are discounted using a pre-tax discount rate that represents the current market risk-free rate and the risks inherent in the asset.

If estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in the income statement.

If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in the income statement if, and only if, the reasons for the impairment loss have ceased to apply.

**Taxation**

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing difference between carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in the income statement, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

**Catalent Pharma Solutions Limited (Registered number: 03761135)**

**Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020**

**2. ACCOUNTING POLICIES - continued**

**Foreign currencies**

Functional currency and presentation currency

The financial statements of the entity are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the financial statements, the results and financial position are presented in pounds sterling.

Transactions and balances

In preparing the financial statements of the entity, transactions in currencies other than the functional currency of the entity (foreign currencies) are recognised at the spot rate at the dates of the transactions or at an average rate where this rate approximates the actual rate at the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences are recognised in the income statement in the period in which they arise.

**Financial instruments**

The company has chosen to adopt the requirements of sections 11 and 12 of FRS102 in respect of the measurement and disclosure of financial instruments.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand, demand deposits with other short-term highly liquid investments with original maturities of three months.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method unless the effect of discounting would be immaterial, in which case they are stated at cost.

Interest-bearing loans and borrowings

All interest-bearing loans and borrowings which are basic financial instruments are initially recognised at the present value of cash payable. After initial recognition they are measured at amortised cost using the effective interest rate method, less impairment. The effective interest rate amortisation is included in finance revenue in the income statement.

The company does not have any 'other' financial instruments.

**3. DIRECTORS EMOLUMENTS**

The directors of the company are also directors or officers of other companies within the Catalent Pharma Solutions Limited group from where they received remuneration for the services rendered. The directors' services to the company do not occupy a significant amount of their time. As such the directors do not consider that they have received any remuneration for their incidental services to the company for the year ended 30 June 2020 (2019: £nil).

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020****4. OPERATING LOSS**

The operating loss is stated after charging:

	2020 £'000	2019 £'000
Auditors- remuneration - audit fees	-	-
Auditors' remuneration – taxation services	-	-
Foreign exchange differences	<u>(30)</u>	<u>22</u>

The company's audit fees were borne by Catalent U.K. Swindon Zydis Limited, a company within the wholly owned Catalent Pharma Solutions group.

**5. INCOME FROM INVESTMENTS**

	2020 £'000	2019 £'000
Gain on sale of investment	<u>3,482</u>	<u>-</u>

In April 2018 a Share Sale Agreement was signed with Blackmores Limited to sell the shares of Catalent Australia Holding Pty Limited to Blackmores Limited for consideration of \$33,000,000 AUD plus a Purchase Price adjustment to be calculated on closing business at date of sale. The closing of the sale took place on 25 October 2019, with the completion payment of \$33,000,000 AUD transferred from Blackmores Limited to Catalent Pharma Solutions Limited. On and from completion, the title and risk of the shares, passed to Blackmores Limited. On 3 March 2020 a final Purchase Price adjustment of \$23,511,668 AUD was agreed, in addition to the completion payment, resulting in a gain of £3,482,178 against the carrying cost of the investment held (see note 9).

**6. INTEREST PAYABLE AND SIMILAR CHARGES**

	2020 £'000	2019 £'000
Group interest payable	<u>10,486</u>	<u>7,871</u>

**7. INTEREST RECEIVABLE AND SIMILAR INCOME**

	2020 £'000	2019 £'000
Group interest receivable	<u>1,380</u>	<u>-</u>

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020****8. TAXATION****a) Analysis of the tax credit**

The tax credit on the loss on ordinary activities for the year was as follows:

	2020 £'000	2019 £'000
<i>Current tax:</i>		
Group relief recoverable	—	—
Tax credit on ordinary activities	—	—

**b) Tax on items charged to equity**

	2020 £'000	2019 £'000
Tax on foreign exchange in OCI	—	—

**c) Reconciliation of total tax credit included in profit and loss**

The tax assessed for the year is higher than (2019: higher than) the standard rate of corporation tax in the UK. The difference is explained below:

	2020 £'000	2019 £'000
Loss on ordinary activities before tax	(5,640)	(7,973)
Loss on ordinary activities multiplied by the standard rate of corporation tax in the UK of 19% (2019 – 19%)	(1,072)	(1,514)
<i>Effects of:</i>		
Disallowable expenditure	—	—
Thin capitalisation adjustment	(720)	(565)
Group relief surrendered	1,792	2,079
Dividends from group companies	—	—
Total tax credit	—	—

**d) Factors that may affect future tax charges**

The Finance Act 2015 was enacted on 15 September 2016 and announced a reduction in the main rate of corporation tax from 20% to 19% from 1 April 2017.



**Catalent Pharma Solutions Limited (Registered number: 03761135)****Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020****9. FIXED ASSET INVESTMENTS**

	Shares in group undertakings £'000
<b>COST</b>	
At 1 July 2019	363,945
Additions	-
Disposals (see note 5)	(27,421)
At 30 June 2020	<u>336,524</u>
<b>PROVISIONS</b>	
At 1 July 2019 and 30 June 2020	<u>274</u>
<b>NET BOOK VALUE</b>	
At 30 June 2020	<u>336,250</u>
At 30 June 2019	<u>363,671</u>

Details of the investments in which the company held 20% or more of the nominal value of any class of share capital at the balance sheet date are listed below. All holdings are 100% owned.

Name of the undertaking	Shares held	Principal activity	Country of incorporation
Catalent U.K Swindon Holding II Limited <sup>1</sup>	Ordinary	Intermediate holding company	England and Wales
Catalent U.K Swindon Zydis Limited <sup>*2</sup>	Ordinary	Development, design and commercialisation of drug delivery systems	Scotland
Catalent U.K Packaging Limited <sup>1</sup>	Ordinary	Manufacture of pharmaceutical unit dose packages and clinical supply services	England and Wales
Catalent Belgium Holding SA <sup>a</sup>	Ordinary	Intermediate holding company	Belgium
Catalent Belgium SA <sup>*a</sup>	Ordinary	Syringe filling services	Belgium
Catalent France Limoges Holding SA <sup>*b</sup>	Ordinary	Intermediate holding company	France
Catalent France Limoges SA <sup>*b</sup>	Ordinary	Syringe filling services	France
CSC Canada Inc. <sup>c</sup>	Ordinary	Manufacture and supply of soft gelatine capsules	Canada

\* owned by subsidiary undertakings

**Registered addresses**

<sup>1</sup> - Frankland Road, Blagrove, Swindon, U.K., SN5 8YG

<sup>2</sup> - Capella Building (Tenth Floor), 60 York Street, Glasgow, G2 8JX

<sup>a</sup> - Font Saint Landry 10, 1120 Neder-Over Heembeek Belgium

<sup>b</sup> - ZI Nord, Rue de Dion Bouton Rue de Dion Bouton, BP 1547 Limoges France

<sup>c</sup> - 160 Elgin Street, Suite 2600, Ottawa, Ontario, K1P 1C3

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020****10. DEBTORS**

	2020 £'000	2019 £'000
Amounts falling due within one year:		
Amounts owed by group undertakings	<u>83,707</u>	<u>4,577</u>
	<u>83,707</u>	<u>4,577</u>
Amounts falling due after more than one year:		
Amounts owed by group undertakings	<u>4,144</u>	<u>4,144</u>
Aggregate amounts	<u>87,851</u>	<u>8,721</u>

The intercompany loans were made to other group entities, they generate interest at a rate of 3 month BP Libor plus 225 bps.

**11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2020 £'000	2019 £'000
Trade creditors	-	-
Trade amounts owed to group undertakings	-	-
Intercompany loans to group undertakings	384,574	327,229
Accruals and deferred income	<u>1</u>	<u>1</u>
	<u>384,575</u>	<u>327,230</u>

The trade amounts owing to group undertakings are non-interest bearing and unsecured.

The intercompany loans to group undertakings are subject to interest at the following rates:

Entity	Interest Rate:	2020 £'000
Catalent Germany Holding III GmbH	3 Month Libor + 275 base points	88,670
Catalent U.K. Packaging Limited	3 Month Libor + 225 base points	94,529
Catalent U.K. Swindon Zydis Limited	3 Month Libor + 225 base points	122,350
Catalent Switzerland 413 AG	3 Month Libor + 225 base points	13,060
Catalent Pharma Solutions GmbH	3 Month Libor + 225 base points	738
Catalent Japan K.K.	3 Month Libor + 225 base points	16,483
Catalent Netherlands Holdings BV	3 Month Libor + 225 base points	8,957
Catalent C T S (Edinburgh) Limited	3 Month Libor + 125 base points	28,589
Catalent Uruguay S.A.	3 Month Libor + 125 base points	10,710
Catalent Pharma Solutions Inc.	3 Month Libor + 125 base points	488

---



---

384,574

The amounts owing to group undertakings are unsecured with no fixed date for repayment.

**Catalent Pharma Solutions Limited (Registered number: 03761135)****Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020****12. CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2020 £	2019 £
3	Ordinary	£1	<u>3</u>	<u>3</u>

**13. RESERVES**

Retained earnings includes all current and prior period retained profits and losses.

**14. FINANCIAL INSTRUMENTS**

The company has the following financial instruments:

	2020 £'000	2019 £'000
Financial assets that are debt instruments measured at amortised cost:		
- Amounts owed by group undertakings	<u>79,059</u>	<u>4,577</u>
	<u>79,059</u>	<u>4,577</u>
Financial liabilities measured at amortised cost:		
- Other creditors	<u>1</u>	<u>1</u>
	<u>1</u>	<u>1</u>

**15. EVENTS AFTER THE REPORTING PERIOD**

On 29 October 2020 Catalent UK Packaging Limited entered into a 45-day consultation period with company employees regarding the potential closure of the site. At the time of signing the financial statements no decision has been reached regarding the potential closure of the site. Catalent Pharma Solutions Inc., the ultimate parent company, has provided a letter of support dated 9 November 2020 to confirm that all intercompany assets of the company will be fulfilled irrespective of the outcome of this consultation period. Accordingly, the statutory accounts for Catalent UK Packaging Limited have been prepared on the going concern basis.

The net assets of Catalent UK Packaging Limited at 30 June 2020 of £112 million exceed the carrying value of the investment of £44 million. Given the strong net assets of Catalent UK Packaging Limited and the letter of support from Catalent Pharma Solution Inc., there is no indicator of impairment to the carrying value of the investment.

On 23 November 2020 Catalent Pharma Solutions Inc repaid £52.9 million of intercompany loans payable to Catalent Pharma Solutions Limited. On the same day, Catalent Pharma Solutions made a capital contribution of £52.9 million to Catalent Brussels Holding S.A., a wholly owned subsidiary. There is no impact to the carrying amount of the investment in these financial statements following this capital infusion.

**16. RELATED PARTY DISCLOSURES**

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. The balances held with related parties are presented in aggregate within notes 10 and 11.

**Catalent Pharma Solutions Limited (Registered number: 03761135)**

**Notes to the Financial Statements - continued**  
**for the Year Ended 30 June 2020**

**17. ULTIMATE PARENT COMPANY AND CONTROLLING PARTY**

Catalent Pharma Solutions Inc., a company incorporated in the USA, is the immediate and ultimate parent undertaking and ultimate controlling party, and heads the group in which the results of the company are consolidated. It is also the smallest group for which consolidated financial statements are publicly available. Copies of these group financial statements may be obtained from:

**Catalent Pharma Solutions Inc.**  
14 Schoolhouse Road  
Somerset  
NJ 08873  
United States of America

or; [investors@catalent.com](mailto:investors@catalent.com)

**18. GUARANTEES**

The company cross guarantees the liabilities of Catalent U.K. Swindon Zydis Limited and Catalent U.K. Packaging Limited for purposes of a composite accounting agreement operated by Barclays Bank. The maximum extent to which a company can become overdrawn under the terms of this arrangement is £7 million. There was no sum outstanding under this guarantee arrangement at the year-end for which the company was indebted to the bank.

## Certificate Of Completion

Envelope Id: 78CD52AA5AA94EB7B3AB32028A929BED

Status: Completed

Subject: Please DocuSign: 20 Catalent Pharma Solutions Limited FY20 - Final.pdf

Source Envelope:

Document Pages: 20

Signatures: 3

Envelope Originator:

Certificate Pages: 4

Initials: 0

Marshall, Becky

AutoNav: Enabled

14 Schoolhouse Rd

Enveloped Stamping: Enabled

Somerset, NJ 08873-1213

Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Becky.Marshall@catalent.com

IP Address: 151.231.199.187

## Record Tracking

Status: Original

Holder: Marshall, Becky

Location: DocuSign

12/9/2020 3:20:05 PM

Becky.Marshall@catalent.com

## Signer Events

## Signature

## Timestamp

Jonathan Arnold

Jonathan.Arnold@catalent.com

President Oral & Specialty Delivery

Catalent Pharma Solutions

Security Level: Email, Account Authentication  
(None)

DocuSigned by:

*Jonathan Arnold*

E3F3CD5850B4428...

Signature Adoption: Pre-selected Style

Using IP Address: 165.225.95.63

Sent: 12/9/2020 3:21:50 PM

Viewed: 12/10/2020 5:56:39 AM

Signed: 12/10/2020 5:56:45 AM

## Electronic Record and Signature Disclosure:

Accepted: 6/14/2017 7:50:45 AM

ID: 41b54d66-3fa3-4e7d-8625-be2ba232e193

## In Person Signer Events

## Signature

## Timestamp

## Editor Delivery Events

## Status

## Timestamp

## Agent Delivery Events

## Status

## Timestamp

## Intermediary Delivery Events

## Status

## Timestamp

## Certified Delivery Events

## Status

## Timestamp

## Carbon Copy Events

## Status

## Timestamp

## Witness Events

## Signature

## Timestamp

## Notary Events

## Signature

## Timestamp

## Envelope Summary Events

## Status

## Timestamps

Envelope Sent

Hashed/Encrypted

12/9/2020 3:21:50 PM

Certified Delivered

Security Checked

12/10/2020 5:56:39 AM

Signing Complete

Security Checked

12/10/2020 5:56:45 AM

Completed

Security Checked

12/10/2020 5:56:45 AM

## Payment Events

## Status

## Timestamps

## Electronic Record and Signature Disclosure

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Catalent Pharma Solutions, Inc. (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your DocuSign, Inc. (DocuSign) Express user account. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. For such copies, as long as you are an authorized user of the DocuSign system you will have the ability to download and print any documents we send to you through your DocuSign user account for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of your DocuSign account. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use your DocuSign Express user account to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through your DocuSign user account all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

**How to contact Catalent Pharma Solutions, Inc.:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: Jean-Marc.Hubsch@catalent.com

**To advise Catalent Pharma Solutions, Inc. of your new e-mail address**

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at Jean-Marc.Hubsch@catalent.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

**To request paper copies from Catalent Pharma Solutions, Inc.**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to Jean-Marc.Hubsch@catalent.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

**To withdraw your consent with Catalent Pharma Solutions, Inc.**

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign account, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to Jean-Marc.Hubsch@catalent.com and in the body of such request you must state your e-mail, full name, US Postal Address, telephone number, and account number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

**Required hardware and software**

Operating Systems:	Windows2000? or WindowsXP?
Browsers (for SENDERS):	Internet Explorer 6.0? or above
Browsers (for SIGNERS):	Internet Explorer 6.0?, Mozilla FireFox 1.0, NetScape 7.2 (or above)
Email:	Access to a valid email account
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	<ul style="list-style-type: none"><li>•Allow per session cookies</li><li>•Users accessing the internet behind a Proxy Server must enable HTTP 1.1 settings via proxy connection</li></ul>

**\*\*** These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time providing you with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.

**Acknowledging your access and consent to receive materials electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I Agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC RECORD AND SIGNATURE DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify Catalent Pharma Solutions, Inc. as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by Catalent Pharma Solutions, Inc. during the course of my relationship with you.